Zeta BRCA-1 Antibody. Zeta’s high quality rabbit recombinant monoclonal antibody recognizes the BRCA-1 protein in immunohistochemistry (IHC) applications. The BRCA-1 gene codes for a nuclear phosphoprotein that plays a role in maintaining genomic stability and acts as a tumor suppressor. Mutations in the BRCA-1 genes have been linked to an increased risk of developing breast and ovarian cancers. Individuals with certain mutations in BRCA-1 may have a higher likelihood of developing these cancers compared to those without the mutations. BRCA-1 immunohistochemistry is commonly used in research and clinical settings to provide valuable information about the status of the BRCA-1 protein in cancerous and non-cancerous tissues. Changes in BRCA-1 protein can be associated with certain types of breast and ovarian cancers, and this information may be used in the diagnosis, prognosis, and treatment planning for patients.
Zeta Corporation is a leader in recombinant monoclonal IVD antibodies for immunohistochemistry (IHC) offering 400+ tumor and tissue specific relevant products developed by a pathologist for pathologists. Visit Precision Recombinant Antibodies – IVD Antibodies – About Zeta Corporation (zeta-corp.com) to learn more about Zeta Corporation.